Inogen (NASDAQ:INGN) Receives "Hold" Rating from Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Inogen (NASDAQ:INGN - Free Report) in a research report report published on Tuesday morning,Benzinga reports.

Separately, StockNews.com lowered Inogen from a "buy" rating to a "hold" rating in a report on Friday, December 20th.

Inogen Stock Up 2.8 %

Shares of INGN stock traded up $0.29 during mid-day trading on Tuesday, reaching $10.62. 342,965 shares of the stock traded hands, compared to its average volume of 201,283. The company has a market cap of $252.95 million, a price-to-earnings ratio of -4.72 and a beta of 1.02. The stock's fifty day simple moving average is $9.49 and its two-hundred day simple moving average is $9.90. Inogen has a 1-year low of $5.08 and a 1-year high of $13.33.

Hedge Funds Weigh In On Inogen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Connor Clark & Lunn Investment Management Ltd. raised its position in Inogen by 312.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock valued at $1,694,000 after purchasing an additional 132,287 shares in the last quarter. Barclays PLC increased its position in shares of Inogen by 72.9% in the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company's stock valued at $539,000 after acquiring an additional 23,398 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in Inogen during the 2nd quarter valued at about $457,000. Geode Capital Management LLC raised its holdings in shares of Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company's stock valued at $5,377,000 after acquiring an additional 5,921 shares in the last quarter. Finally, Divisadero Street Capital Management LP raised its holdings in Inogen by 682.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company's stock worth $19,079,000 after purchasing an additional 2,046,766 shares in the last quarter. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.